Riskpilot← Back to searchSign inGet full accessBimelix Ab
OYActiveY-tunnus 2302777-5Lövuddsvägen 4Other human health activities n.e.c. · NACE 8699Est. 2009— employees
Revenue 2024
EUR 0
EBITDA margin
—
Equity ratio
89.3%
Financial strength
Net profit 2024
EUR -85K
-13% vs 2023
| Revenue | EUR 0 | — |
| EBITDA | EUR -47K | — |
| Net profit | EUR -85K | -13% |
| Total assets | EUR 740K | -21% |
| Equity | EUR 660K | -24% |
| Employees | — | — |
Legal name
Bimelix Ab
Y-tunnus number
2302777-5
Legal form
Osakeyhtiö
NACE code
8699 · Other human health activities n.e.c.
Founded
3. joulukuuta 2009
Share capital
EUR 2 500
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Bolagets verksamhetsområde är biomedicinsk laboratorieverksamhet samt därtill ansluten verksamhet.
Address
Lövuddsvägen 4
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 572 | 583 | 1 498 | 2 926 | 0 | 0 |
| Staff expenses | −145 | −172 | −229 | −278 | −0 | −0 |
| EBITDA | 152 | 132 | 606 | 1 332 | 0 | −47 |
| Depreciation & amort. | −11 | −12 | −272 | −166 | −0 | −32 |
| EBIT | 141 | 120 | 334 | 1 166 | 0 | −79 |
| Net financials | −31 | −11 | −7 | 3 | 13 | −0 |
| Profit before tax | 107 | 103 | 328 | 1 174 | 16 | −85 |
| Tax | −0 | 10 | 64 | 235 | 1 | −0 |
| Net profit | 107 | 93 | 264 | 939 | −75 | −85 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 509 | 641 | 736 | 1 656 | 941 | 740 |
| Equity | 113 | 211 | 474 | 1 304 | 865 | 660 |
| Long-term debt | 151 | 162 | 62 | 1 | 0 | 0 |
| Short-term debt | 245 | 268 | 202 | 351 | 74 | 71 |
| Total debt | 396 | 430 | 263 | 352 | 74 | 71 |
EBITDA margin
-4682200.0%
This company
15.8%
Market median
-29634277% vs market
20192024
Equity ratio
89.3%
This company
38.2%
Market median
+134% vs market
20192024
Return on equity
-12.9%
This company
18.4%
Market median
-170% vs market
20192024
Net profit margin
-8526800.0%
This company
8.1%
Market median
-105269236% vs market
20192024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20192024
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20192024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via PRH / YTJ · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Audit | 2016 | — | — | |
SH Person with significant control | Person with significant control | 2009 | — | — |
MT Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2016 | — | — | |
| Chairperson | 2016 | — | — | |
| Board of Directors | 2016 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Bimelix Ab also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lilli Fanny Kristiina Johansson | Audit | 0 companies |
| Susanne Helen Olausson | Person with significant control | 0 companies |
| Mathias Tomas Saladin Grunér | Chief Executive Officer | 0 companies |
| Sten-Anders Carlsson | Board of Directors | 0 companies |
| Johanna Marina Wahlberg | Board of Directors | 0 companies |
| Sven-Harry Arthur Boman | Chairperson | 0 companies |
| Dag Nyman | Board of Directors | 0 companies |